Atomo Diagnostics Ltd
Atomo Diagnostics Limited is an Australia-based medical device company.
The business
Atomo Diagnostics Limited is an Australia-based medical device company. The Company supplies integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The Company’s patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialized a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiations as well as the early detection of pregnancy. Its products include Atomo HIV Self-Test, AtomoRapid Pascal and AtomoRapid Curie, among others. Its Atomo HIV Self-Test is an integrated, blood-based rapid diagnostic test (RDT) for HIV screening, which provides results in 15 minutes. The AtomoRapid Pascal platform offers improved performance and usability in point of care testing.
Small Caps Research
No research on Atomo Diagnostics Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise AT1 based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Atomo Diagnostics to supply HIV test kits across SA and Victoria as part of national vending machine program
Atomo Diagnostics (ASX: AT1) has received a $230,000 order from Thorne Harbour Health for HIV Self Test kits to support a national scale-up of the federal government’s CONNECT program, which provides free kits through vending machines. Thorne’s order will supply kits to machines across South Australia and Victoria as part of the government’s pilot program […]
Weekly wrap: WiseTech relief rally helps market to bounce higher
After days of fairly salacious headlines around WiseTech founder Richard White and his penchant for delivering mansions to girlfriends, the company pushed the entire Australian market into making a small gain. News that Mr White would step aside as chief executive but will return in a full-time product and business development consulting role led to […]
Atomo Diagnostics secures $2.44m grant to develop first rapid active syphilis self-test
Atomo Diagnostics (ASX: AT1) has again been recognised by the Australian government with the award of a $2.44 million grant to develop a unique syphilis test. The Australian-based medical device company was awarded the CRC-P industry grant from the Department of Industry, Science and Resources (DISR) to support the development of an innovative rapid active […]
Atomo Diagnostics boosted by federal funding for HIV prevention and self-test expansion
Medical device company Atomo Diagnostics (ASX: AT1) has welcomed the Australian government’s commitment to fund the expansion of self-testing procedures for human immunodeficiency virus (HIV) in this week’s federal budget. The company anticipates that a significant portion of the $43.9 million committed to HIV prevention will be used for the procurement of more of its […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.